Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).

NCT00143312 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00143312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2005
Completion date
April 30, 2008
Enrollment
45 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prophylaxis of invasive fungal infections